[TABLE OF CONTENTS]

1 INTRODUCTION OF GLOBAL CANCER BIOMARKERS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY: CANCER BIOMARKERS MARKET

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS

4 GLOBAL CANCER BIOMARKERS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE

5 GLOBAL CANCER BIOMARKERS MARKET, BY TYPE
5.1 OVERVIEW
5.2 BREAST CANCER
5.3 PROSTATE CANCER
5.4 COLORECTAL CANCER
5.5 CERVICAL CANCER
5.6 LIVER CANCER
5.7 LUNG CANCER
5.8 OTHERS

6 GLOBAL CANCER BIOMARKERS MARKET, BY BIOMOLECULE
6.1 OVERVIEW
6.2 GENETIC BIOMARKERS
6.3 EPIGENETIC BIOMARKERS
6.4 METABOLIC BIOMARKERS
6.5 PROTEOMIC BIOMARKERS
6.6 OTHERS

7 GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 DRUG DISCOVERY AND DEVELOPMENT
7.3 DIAGNOSTICS
7.4 PERSONALIZED MEDICINE
7.5 OTHERS 

8 GLOBAL CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY
8.1 OVERVIEW
8.2 OMIC TECHNOLOGIES
8.3 IMAGING TECHNOLOGIES
8.4 IMMUNOASSAYS
8.5 CYTOGENETICS-BASED TESTS

9 GLOBAL CANCER BIOMARKERS MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 ACADEMIC AND CANCER RESEARCH INSTITUTES
9.4 AMBULATORY SURGICAL CENTRES
9.5 DIAGNOSTIC LABORATORIES 

10 GLOBAL CANCER BIOMARKERS MARKET, BY GEOGRAPHY
10.1 OVERVIEW

10.2 NORTH AMERICA

10.2.1 NORTH AMERICA MARKET SNAPSHOT
10.2.2 U.S.
10.2.3 CANADA
10.2.4 MEXICO

10.3 EUROPE

10.3.1 EUROPE MARKET SNAPSHOT
10.3.2 WESTERN EUROPE
10.3.2.1 THE UK
10.3.2.2 GERMANY
10.3.2.3 FRANCE
10.3.2.4 ITALY
10.3.2.5 SPAIN
10.3.2.6 REST OF WESTERN EUROPE
10.3.3 EASTERN EUROPE
10.3.3.1 POLAND
10.3.3.2 RUSSIA
10.3.3.3 REST OF EASTERN EUROPE

10.4 ASIA PACIFIC

10.4.1 ASIA PACIFIC MARKET SNAPSHOT
10.4.2 CHINA
10.4.3 JAPAN
10.4.4 INDIA
10.4.5 AUSTRALIA & NEW ZEALAND
10.4.6 ASEAN
10.4.7 REST OF ASIA PACIFIC

10.5 MIDDLE EAST & AFRICA

10.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
10.5.2 UAE
10.5.3 SAUDI ARABIA
10.5.4 SOUTH AFRICA
10.5.5 REST OF MEA

10.6 SOUTH AMERICA

10.6.1 SOUTH AMERICA MARKET SNAPSHOT
10.6.2 BRAZIL
10.6.3 ARGENTINA
10.6.4 REST OF SOUTH AMERICA

11 GLOBAL CANCER BIOMARKERS MARKET COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPANY MARKET RANKING
11.3 KEY DEVELOPMENT STRATEGIES
11.4 COMPETITIVE DASHBOARD
11.5 PRODUCT MAPPING
11.6 TOP PLAYER POSITIONING, 2022
11.7 COMPETITIVE HEATMAP
11.8 TOP WINNING STRATEGIES

12 COMPANY PROFILES

12.1 F. HOFFMANN-LA ROCHE LTD.
12.1.1 OVERVIEW
12.1.2 FINANCIAL PERFORMANCE
12.1.3 PRODUCT OUTLOOK
12.1.4 KEY DEVELOPMENTS
12.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.2 THERMO FISHER SCIENTIFIC INC.
12.2.1 OVERVIEW
12.2.2 FINANCIAL PERFORMANCE
12.2.3 PRODUCT OUTLOOK
12.2.4 KEY DEVELOPMENTS
12.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.3 QIAGEN N.V.
12.3.1 OVERVIEW
12.3.2 FINANCIAL PERFORMANCE
12.3.3 PRODUCT OUTLOOK
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.4 ILLUMINA INC.
12.4.1 OVERVIEW
12.4.2 FINANCIAL PERFORMANCE
12.4.3 PRODUCT OUTLOOK
12.4.4 KEY DEVELOPMENTS
12.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.5 BIO-RAD LABORATORIES INC.
12.5.1 OVERVIEW
12.5.2 FINANCIAL PERFORMANCE
12.5.3 PRODUCT OUTLOOK
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.6 ABBOTT LABORATORIES
12.6.1 OVERVIEW
12.6.2 FINANCIAL PERFORMANCE
12.6.3 PRODUCT OUTLOOK
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.7 ABBOTT LABORATORIES
12.7.1 OVERVIEW
12.7.2 FINANCIAL PERFORMANCE
12.7.3 PRODUCT OUTLOOK
12.7.4 KEY DEVELOPMENTS
12.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.8. MESO SCALE DIAGNOSTICS LLC 
12.8.1 OVERVIEW
12.8.2 FINANCIAL PERFORMANCE
12.8.3 PRODUCT OUTLOOK
12.8.4 KEY DEVELOPMENTS
12.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.9 SEEGENE TECHNOLOGIES INC.
12.9.1 OVERVIEW
12.9.2 FINANCIAL PERFORMANCE
12.9.3 PRODUCT OUTLOOK
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

12.10 SIEMENS HEALTHINEERS
12.10.1 OVERVIEW
12.10.2 FINANCIAL PERFORMANCE
12.10.3 PRODUCT OUTLOOK
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS